Posts

Posted on

DZS to Provide FTTx, 5G Technology and Market Outlook at FTTH Conference 2020

PLANO, Texas, Nov. 30, 2020 (GLOBE NEWSWIRE) — DZS (NASDAQ: DZSI), a broadband access innovator and global market leader spanning fixed and mobile edge access and connected premises solutions for service providers and enterprises, today announced CTO Andrew Bender and other senior company leaders will be presenting at the FTTH Virtual Conference 2020 on 2 December, 2020. These DZS executives and other experts from the FTTH and 5G ecosystem will share timely perspectives on current FTTx innovation, its impact on the acceleration of 5G deployments, and a market outlook across these technologies in Europe and beyond. The FTTH Conference has distinguished itself as one of the world’s largest meeting places for broadband stakeholders, bringing together technology and regulatory experts and investors to discuss and debate all aspects of FTTH, 5G and other fiber-related innovation. DZS is a Gold sponsor for FTTH Virtual Conference 2020.

Mr. Bender will present “10Gig PON … the Catalyst for the 5G Business Case” as part of the “Delivering the PON and Fibre Ecosystem: 2020 Lessons Learned and 2021 Realities” workshop from 14.00 to 15.30 CET. This 90-minute Broadband Acceleration Seminar (BASe), organized and moderated by Broadband Forum, will unite senior technologists in a discussion on how passive optical network (PON) access networks have performed and what FTTH innovations will improve the user experience for fixed, 5G and fixed mobile convergence and the delivery of better fiber broadband experience. It will also explore the technology trends that will make next-generation PON technologies a reality. Other participants will include Nokia, Calix and EXFO.

“The FTTH market in Europe, the Middle East and Africa (EMEA) is accelerating and predicted to be one of the world’s fastest growing PON markets over the next five years, with a CAGR of 9.5% according to Omdia,” said Mr. Bender. “This growth, in turn, is expected to lay the foundations for rapid 5G deployments in this region and around the world. I am pleased to be joining other forward-thinking technologists to discuss the latest innovations, market trends, lessons learned and deployment realities that will guide the industry in 2021 and beyond. The intersection of 10Gig PON and 5G is starting to happen now, and today is a critical time for service providers to prepare their networks for the future.”

Following Mr. Bender’s session, DZS leadership in EMEA will present “FTTH in Germany – Approaches for Accelerating the Adoption of FTTH” as part of a workshop from 16.00 to 17.30 CET. Organized by DZS FTTH Council Primary Delegate and Head of EMEA Services Frank Beyrodt, this session will include presentations and perspectives from Hamburg Commercial Bank, Berenberg Bank, Tele-Kabel-Ingenieurgesellschaft (TKI) and DZS Director of Product Line Management Jochen Krauss. The workshop will highlight the key role of GIS, resource and service inventories in driving automation, acceleration and cost-reduction of FTTH, as well as 5G planning, deployment, service fulfillment and service assurance. Workshop experts will explore market drivers, inhibitors, and financial challenges with various approaches to advancing FTTH in Germany’s banking sector, as well as recap the technology trends influencing networking designs and solutions. Mr. Krauss will complement these perspectives, providing an FTTH technology and market outlook, including how COVID-19 has impacted traffic growth, the barriers of mass adoption to fiber-based networks solutions, advancing network technologies’ role in network optimization potential, and network convergence’s growing relationship with fiber and 5G.

To find out more about the DZS presence at the show, visit https://ftthconference.eu/conference-workshop-programme/programme-details.

For more information about DZS and its FTTx access solutions and PON technology, visit https://dzsi.com/fttx/.

About DZS

DZS Inc. (NSDQ: DZSI) is a broadband access innovator and global market leader spanning fixed and mobile edge access and connected premises solutions for service providers and enterprises. A pioneer in broadband access and mobile AnyHaul platforms with over 20 million products shipped, service providers and enterprises look to DZS for the innovation that leads to future-proof networks and outstanding performance. Over 1,000 service providers, operators, and enterprises in over 100 countries have leveraged DZS innovation, open solutions, and agility to arm them with the network resources and deployment freedom they need to lead in their markets and deliver an unrivaled communications experience. With manufacturing, engineering, service and support centers of excellence spread across the globe, DZS is positioned to bring next-generation technologies and world-class solutions to service providers and enterprises who are poised to transform, compete and win.

DZS, the DZS logo, and all DZS product names are trademarks of DZS Inc. Other brand and product names are trademarks of their respective holders. Specifications, products, and/or product names are all subject to change.

This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Private Securities Litigation Reform Act of 1995. These statements reflect the beliefs and assumptions of the Company’s management as of the date hereof. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” variations of such words, and similar expressions are intended to identify forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. The Company’s actual results could differ materially and adversely from those expressed in or contemplated by the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, those risk factors contained in the Company’s SEC filings available at www.sec.gov, including without limitation, the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings. In addition, additional or unforeseen affects from the COVID-19 pandemic and the global economic climate may give rise to or amplify many of these risks. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. DZS undertakes no obligation to update or revise any forward-looking statements for any reason.

For further information see: https://dzsi.com/.
DZS on Twitter: https://twitter.com/dzs_innovation
DZS on LinkedIn: https://www.linkedin.com/company/dzsi/

Press Inquiries:

McKenzie Hurst, Thatcher+Co.
Mobile: +1 408.888.6787
Email: [email protected]

 



Posted on

Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners

  • I
    n-licensing
    of
    four clinical-stage product candidates
    to
    treat
    orphan
    neurological
    disorders
  • Highly experienced team leverages latest scientific discoveries in neuroscience
  • Financing will
    advance
    the
    development of
    four
    clinical
    –
    stage
    product
    candidates
  • Strong participation from international syndicate of investors, including
    Gilde Healthcare, Invus and BioMed Partners
  • Sofinnova Partners
    seed-financed
    Noema in 2019

BASEL, Switzerland, Dec. 01, 2020 (GLOBE NEWSWIRE) — Noema Pharma (‘Noema”) AG, a Swiss clinical-stage company targeting orphan neurological disorders, today announced it has successfully concluded an oversubscribed Series A financing round, raising CHF54 million ($59 million USD) to fund further development of its promising clinical-stage pipeline. The round was co-led by Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, and Polaris Partners, a healthcare and technology investment firm based in the United States. The global consortium of new international investors includes Gilde Healthcare, Invus and BioMed Partners. Roche, the Swiss multinational healthcare company, received a shareholding in Noema in exchange for rights to four clinical-stage product-candidates.

Darren Carroll of Polaris Partners and Arthur Franken of Gilde Healthcare join Antoine Papiernik of Sofinnova Partners on the Company’s Board of Directors.

A 2019 seed investment from Sofinnova Partners formed Noema. From the outset, Noema has been leveraging the latest scientific discoveries in neuroscience to identify and pursue promising new indications, and to elaborate a strategy around the four product candidates it licensed from Roche.

Luigi Costa, Chief Executive Officer, said: “The successful licensing of these exciting clinical-stage product-candidates from Roche, together with our up-sized CHF54 million Series A financing, will enable Noema to reach value-creating development milestones with all four products. We are honored to have garnered continued support from our seed investor, Sofinnova Partners, and to have attracted Polaris Partners as a co-lead investor. We are equally pleased to welcome highly experienced specialist investors Gilde Healthcare, Invus and BioMed Partners. We are now in a solid position to continue advancing these potentially life-changing therapeutics for patients who have no satisfactory treatment options.”

The product candidates will be developed in neurological indications with severe unmet need, such as seizures in tuberculosis sclerosis complex (TSC), trigeminal neuralgia, Tourette syndrome and other rare neurological disorders.

George Garibaldi, MD, Chief Medical Officer, said: “The strong clinical and preclinical safety packages generated at Roche will enable us to swiftly pursue a series of clinical programs in orphan CNS indications. Our analyses, based on new scientific evidence, have led us to indications upon which we have been building new intellectual property and efficient development and regulatory strategies. Across all our clinical initiatives, we focus on partnering with patients and patient associations to gather their input on what matters to them.”

Mr. Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “Noema’s successful Series A financing substantiates our early conviction in the tremendous potential of this team and the work they have done thus far to bring groundbreaking therapies to patients with debilitating neurological disorders. Luigi, George and John Kemp, Noema’s Chief Scientific Officer, have been instrumental in laying the foundations of this company and now, bolstered by this significant investment, they are in a strong position to further progress Noema’s promising product candidates into the clinic.”

Mr. Carroll, Partner at Polaris Partners, said: “Noema is a prime example of the exceptional pharma-grade assets Europe has to offer, along with a flourishing talent pool. We are delighted to co-lead this round of global investors and look forward to working with Noema to make this a global success.”

LifeSci Advisors acted as investor relations advisor to Noema.

About Noema Pharma

Noema Pharma (www.noemapharma.com) is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages. Lead product NOE-101, an mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN). NOE-105, a PDE10A inhibitor, is in preparation for Phase 2b testing to treat Tourette Syndrome. The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, an mGluR2/3 inhibitor, and NOE-115, a triple re-uptake inhibitor. Noema Pharma was founded with the leading venture capital firm Sofinnova Partners. Investors include Polaris Partners, Gilde Healthcare, Invus and Biomed Partners.

About
Sofinnova Partners

Sofinnova Partners (www.sofinnovapartners.com) is a leading European venture capital firm specialized in Life Sciences. Based in Paris, London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed 500 companies over 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.

About Polaris Partners

Polaris Partners (www.polarispartners.com) has a 20-plus-year history of partnering with repeat entrepreneurs and world-class innovators who are improving the way we live and work. The multibillion-dollar firm manages specialty and diversified funds in healthcare and technology with investments across all stages. Polaris has offices in Boston, San Francisco, and New York.

About Gilde Healthcare

Gilde Healthcare (www.gildehealthcare.com) is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in therapeutics, medtech and digital health. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region.

About
Invus

Invus (www.invus.com) is a global investment firm with principal offices in New York, Paris and Hong Kong whose source of capital since its founding in 1985 has been a European family group. The exceptional returns from Invus’ evergreen investment strategy have allowed a modest initial pool of capital to grow to over $8 billion even after having distributed billions to shareholders. Invus doesn’t raise any outside funds and focuses all its energy on value creation. On the private side, Invus mostly takes majority control positions in companies that have ambitious transformational strategies but also makes minority investments in high-growth companies where it can add real strategic value through its partnership with owner-managers. On the public side, Invus takes significant long-only, long-term positions in companies whose fundamentals and management it believes in. The average holding period in the public equity portfolio is not measured in weeks or months but years.

About
BioMed Partners

BioMed Partners (www.biomedvc.com), based in Basel, Switzerland is an independent venture capital firm that has established itself as a leading investor in early-stage biotech companies in Europe. In its third fund, raised in 2018, BioMed Partners focuses on the build-up of companies with highly innovative assets and technology platforms as well as on strong, entrepreneurial teams. The first investment of BioMedInvest III was in the Swiss immuno-oncology company Amal SA (Geneva) in 2017, which was subsequently acquired by Boehringer Ingelheim in June 2019.

Contacts

Noema Pharma

Luigi Costa
Chief Executive Officer
[email protected]		 Investors & Media

LifeSci Advisors – Ligia Vela-Reid
[email protected]
+44 (0) 7413 825310



Posted on

MarketAxess Completes Acquisition of Regulatory Reporting Hub From Deutsche Börse Group

NEW YORK and AMSTERDAM, Dec. 01, 2020 (GLOBE NEWSWIRE) — MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, and the provider of market data and post-trade services for the global fixed-income markets, has completed its previously announced acquisition of Regulatory Reporting Hub, the regulatory reporting business of Deutsche Börse Group. MarketAxess acquired the business through Trax NL B.V., its wholly owned subsidiary in the Netherlands, on 30 November 2020.

Christophe Roupie, Head of EMEA and APAC at MarketAxess, commented: “We’re delighted to welcome clients of the Regulatory Reporting Hub to MarketAxess. This acquisition is a firm demonstration of our long-term commitment to building our regulatory reporting infrastructure across Europe. It will help us to extend the full front-to-back trade lifecycle services that we offer, from trading and data through to reporting and regulatory compliance. We look forward to working with Deutsche Börse Group over the coming months to successfully transition all our new clients to MarketAxess services.”

About MarketAxess

MarketAxess operates a leading, institutional electronic trading platform delivering expanded liquidity opportunities, improved execution quality and significant cost savings across global fixed-income markets. A global network of over 1,700 firms, including the world’s leading asset managers and institutional broker-dealers, leverages MarketAxess’ patented trading technology to efficiently trade bonds. MarketAxess’ award-winning Open Trading™ marketplace is regarded as the preferred all-to-all trading solution in the global credit markets, creating a unique liquidity pool for a broad range of credit market participants. Drawing on its deep data and analytical resources, MarketAxess provides automated trading solutions, market data products and a range of pre- and post-trade services.

MarketAxess is headquartered in New York and has offices in London, Amsterdam, Boston, Chicago, Los Angeles, Miami, San Francisco, São Paulo, Hong Kong and Singapore. For more information, please visit www.marketaxess.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including statements about the outlook and prospects for Company and industry growth, as well as statements about the Company’s future financial and operating performance. These and other statements that relate to future results and events are based on MarketAxess’ current expectations. The Company’s actual results in future periods may differ materially from those currently expected or desired because of a number of risks and uncertainties, including: risks relating to the COVID-19 pandemic, including the possible effects of the economic conditions worldwide resulting from the COVID-19 pandemic; global economic, political and market factors; the volatility of financial services markets generally; the level of trading volume transacted on the MarketAxess platform; the absolute level and direction of interest rates and the corresponding volatility in the corporate fixed-income market; the level and intensity of competition in the fixed-income electronic trading industry and the pricing pressures that may result; the variability of our growth rate; the rapidly evolving nature of the electronic financial services industry; our ability to introduce new fee plans and our clients’ response; our exposure to risks resulting from non-performance by counterparties to transactions executed between our clients in which we act as an intermediary in matched principal trades; risks related to self-clearing; our dependence on our broker-dealer clients; the loss of any of our significant institutional investor clients; our ability to develop new products and offerings and the market’s acceptance of those products; the effect of rapid market or technological changes on us and the users of our technology; our ability to successfully maintain the integrity of our trading platform and our response to system failures, capacity constraints and business interruptions; our vulnerability to cyber security risks; our ability to protect our intellectual property rights or technology and defend against intellectual property infringement or other claims; our ability to enter into strategic alliances and to acquire other businesses and successfully integrate them with our business; our ability to comply with new and existing laws, rules and regulations both domestically and internationally; our ability to maintain effective compliance and risk management methods; the strain of growth initiatives on management and other resources; our future capital needs and our ability to obtain capital when needed; limitations on our operating flexibility contained in our credit agreement; and other factors. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. More information about these and other factors affecting MarketAxess’ business and prospects is contained in MarketAxess’ periodic filings with the Securities and Exchange Commission and can be accessed at www.marketaxess.com.

MarketAxess
Media Relations Contacts: 		 
New York:
Kyle White
+1 212 813 6355
[email protected]		 London:
Toby West
+44 (0)20 7709 3270
[email protected]

MarketAxess
Investor Relations Contact:

David Cresci
+1 212 813 6027
[email protected]



Posted on

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET

NEW YORK and LONDON, Dec. 01, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (NASDAQ: TLSA) (“Tiziana” or the “Company“), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on the Company. Dr. Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences.

Date: Wednesday, 2 December 2020
Time: 4:15 p.m. Eastern Time
Live Call: +1-877-425-9470 (U.S. Toll-Free) or +1-201-389-0878 (International)
Webcast: http://public.viavid.com/index.php?id=142634

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until 16 December 2020 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13713850.

About
Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn’s disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.


For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder		 +44 (0)20 7495 2379

United States Investors:

Dave Gentry
RedChip Companies Inc.

 Office 1 800 RED CHIP (733 2447)
Cell 407-491-4498 (USA)
[email protected]



Posted on

Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lymphoma

PR Newswire

OSLO, Norway, Dec. 1, 2020 /PRNewswire/ — Nordic Nanovector ASA (OSE: NANO) announces that it has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT).

Eighteen DLBCL patients were enrolled into the trial at clinical trial sites in the US and Europe and were dosed with three escalating treatment doses of Betalutin® (10MBq/kg, 15MBq/kg and 20MBq/kg). A preliminary data readout is expected in H1’2021.

As announced in April 2020, LYMRIT 37-05 will be paused pending analysis of these data, which is expected to inform plans for the further development of Betalutin® in R/R DLBCL.

Nordic Nanovector’s primary focus is the timely completion of the pivotal Phase 2b PARADIGME trial of Betalutin® in 3rd-line follicular lymphoma (3L FL).


Christine Wilkinson Blanc, Chief Medical Officer of Nordic Nanovector, said: “The completion of recruitment into this dose-finding study in patients with DLBCL is an important milestone. DLBCL remains a significant indication with a large unmet medical need. The data analysis from this trial will form the basis of our considerations for the further development of Betalutin® in DLBCL and more broadly across non-Hodgkin’s lymphoma.”

The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation study in DLBCL designed to determine the dose to be recommended for further studies in DLBCL and assess the safety, tolerability, pharmacokinetic profile and preliminary anti-tumour activity of a single administration of Betalutin®. More information on this study can be found at www.clinicaltrials.gov (NCT02658968).

DLBCL is an aggressive form of non-Hodgkin’s Lymphoma (NHL) that accounts for 30% of all NHL cases1,2. The number of diagnosed incident cases of DLBCL in the seven major markets (US, key five European markets and Japan) was 64,172 in 2018 and is expected to grow to 74,927 in 20283.

Approximately 40% of DLBCL patients relapse after first-line combination treatment with rituximab and chemotherapy. These patients have few therapeutic options, with high-dose chemotherapy and autologous stem cell transplant (ASCT) achieving long-term remissions in only a minority of patients4. Relapsed DLBCL therefore remains a serious unmet medical need.

References

  1. Siegel R, Miller K and Jemal A. Cancer Statistics, 2019. CA Cancer J. Clin. 2019;69(1):7–34
  2. https://www.lls.org/lymphoma/non-hodgkin-lymphoma/diagnosis/nhl-subtypes 
  3. Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL), 2020, Decision Resources Group, Clarivate
  4. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019 May;94(5):604-616.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: [email protected]

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: [email protected]

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.


Forward-looking statements

This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-completes-patient-enrolment-into-phase-1-trial-of-betalutin–in-diffuse-large-b-ce,c3246599

Cision View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-completes-patient-enrolment-into-phase-1-trial-of-betalutin-in-diffuse-large-b-cell-lymphoma-301182172.html

SOURCE Nordic Nanovector

Posted on

Nidec Announces the Status of Own Share Repurchase

(Repurchase of own shares, pursuant to the Company’s Articles of Incorporation based on the provisions of Article 459-1-1 of the Company Law of Japan)

KYOTO, Japan, Dec. 01, 2020 (GLOBE NEWSWIRE) — Nidec Corporation (TSE: 6594; OTC US: NJDCY) (the “Company”) today announced the status of the Company’s own share repurchase under its ongoing repurchase plan resolved at a meeting of the Board of Directors held on January 23, 2020, and February 8, 2020, pursuant to Article 459, Paragraph 1, Item 1 of the Company Law of Japan.

Details are as follows:

Details of Share Repurchase 　

1. Period of own share repurchase: From November 1, 2020 through November 30, 2020
2. Class of shares: Common stock
3. Number of own shares repurchased: 0
4. Total repurchase amount: 0 yen

Note: The above repurchase information has been prepared on the basis of trade date.

Reference

A) The following details were resolved by the Company’s Board of Directors on January 23, 2020 and February 8, 2020:
1. Class of shares: Common stock
2. Total number of shares that may be repurchased: Up to 8,000,000 shares　
    (1.36% of total number of shares issued, excluding treasury stock)
3. Total repurchasable amount: 50 billion yen
4. Period of repurchase: From January 24, 2020 through January 22, 2021

B) Total number and yen amount of own shares repurchased from January 24, 2020 through November 30, 2020, pursuant to the Board of Directors resolution above:
1. Total number of own shares repurchased: 2,850,200
2. Total repurchase amount: 18,527,768,000 yen

Contact:
Masahiro Nagayasu
General Manager
Investor Relations
+81-75-935-6140

[email protected]

 



Posted on

Onex Partners Announces Secondary Sale of SIG Combibloc

All amounts
in U.S. dollars 
unless otherwise stated

TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) — Onex Corporation (“Onex”) (TSX: ONEX) and its affiliated funds (the “Onex Group”) today announced they sold their remaining approximately 32.3 million shares of SIG Combibloc Group (“SIG”) (SIX: SIGN), a leading systems and solutions provider for aseptic carton packaging. After this sale, the Onex Group will cease to hold any shares of SIG.

Nigel Wright, Senior Managing Director of Onex Partners, commented, “With this sale we have exited our investment in SIG Combibloc. We are honoured to have been part of SIG’s journey over the last nearly six years, as it has grown around the world, expanded its product portfolio, and continued to offer first-rate solutions to its customers. We wish everyone at SIG the best of success in the years to come.”

At the transaction price of CHF 20.35 per share, gross proceeds to the Onex Group will be approximately $725 million, of which Onex’ share will be approximately $225 million as a Limited Partner in Onex Partners IV and as a co-investor.

The transaction, which was made through an accelerated bookbuilding process to institutional investors, is expected to close on December 3, 2020, subject to customary closing conditions.

This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any of these securities in the United States, Australia, Canada or Japan or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification or the publication of a prospectus under the securities laws of any such jurisdiction. The securities may not be offered or sold in the United States absent registration or an applicable exemption from United States registration requirements. No public offer of securities is to be made in the United States, Australia, Canada or Japan. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law.

This announcement is not an offer of securities for sale in or into the United States. The shares of SIG have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or under the laws of any State of the United States and may not be offered or sold in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No public offering of securities will be made in the United States.

This announcement and any offer of securities to which it relates are only addressed to and directed at persons who are (1) qualified investors as defined under Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and (2) who have professional experience in matters relating to investments who fall within article 19(1) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or are persons falling within article 49(2)(A) to (D) (“High net worth companies, unincorporated associations, etc.”) of the Order or are persons to whom an offer of the placement shares may otherwise lawfully be made.

With respect to each member state of the European Economic Area and the United Kingdom (each a “Relevant State”), no offer of the shares has been made and will not be made to the public in that Relevant State in accordance with the Prospectus Regulation, no action has been undertaken or will be undertaken to make an offer to the public of the shares sold by the investors requiring a publication of a prospectus in any Relevant State. As a consequence, the shares may only be offered or sold in any Relevant State pursuant to an exemption under the Prospectus Regulation.

No action has been taken by Onex or any of its affiliates that would permit an offering of such shares or possession or distribution of this announcement or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required. Persons into whose possession this announcement comes are required by Onex to inform themselves about, and to observe, any such restrictions. Persons (including, without limitation, nominees and trustees) who have a contractual or other legal obligation to forward a copy of this announcement should seek appropriate advice before taking any action.


About Onex


Founded in 1984, Onex invests and manages capital on behalf of its shareholders, institutional investors and high net worth clients from around the world. Onex’ platforms include: Onex Partners, private equity funds focused on larger opportunities in North America and Europe; ONCAP, private equity funds focused on middle market and smaller opportunities in North America; Onex Credit, which manages primarily non-investment grade debt through collateralized loan obligations, senior loan strategies and other private credit strategies; and Gluskin Sheff’s wealth management services including its actively managed public equity and public credit funds. In total, Onex has approximately $36.6 billion of assets under management, of which approximately $6.7 billion is its own shareholder capital. With offices in Toronto, New York, New Jersey and London, Onex and its experienced management teams are collectively the largest investors across Onex’ platforms.

The Onex Partners and ONCAP businesses have assets of $36 billion, generate annual revenues of $22 billion and employ approximately 149,000 people worldwide. Onex shares trade on the Toronto Stock Exchange under the stock symbol ONEX. For more information on Onex, visit its website at www.onex.com. Onex’ security filings can also be accessed at www.sedar.com.


Forward-Looking Statements


This press release may contain, without limitation, statements concerning possible or assumed future operations, performance or results preceded by, followed by or that include words such as “believes”, “expects”, “potential”, “anticipates”, “estimates”, “intends”, “plans” and words of similar connotation, which would constitute forward-looking statements. Forward-looking statements are not guarantees. The reader should not place undue reliance on forward-looking statements and information because they involve significant and diverse risks and uncertainties that may cause actual operations, performance or results to be materially different from those indicated in these forward-looking statements. Except as may be required by Canadian securities law, Onex is under no obligation to update any forward-looking statements contained herein should material facts change due to new information, future events or other factors. These cautionary statements expressly qualify all forward-looking statements in this press release.


For Further Information


Jill Homenuk
Managing Director, Shareholder Relations and Communications
Tel: 416.362.7711



Posted on

SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – CLCT, INFO, SNSS, RESI, CIT

PR Newswire

NEW YORK, Dec. 1, 2020 /PRNewswire/ —

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:


Collectors Universe, Inc. (NASDAQ: CLCT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to an investor group led by entrepreneur and sports card collector Nat Turner, D1 Capital Partners L.P., and Cohen Private Ventures, LLC for $75.25 per share. If you are a Collectors Universe shareholder, click here to learn more about your rights and options.  


IHS Markit Ltd.
 (NYSE: INFO) concerning potential violations of law relating to its sale to S&P Global Inc. Under the terms of the merger agreement, each share of IHS Markit common stock will be exchanged for a fixed ratio of 0.2838 shares of S&P Global common stock. If you are an IHS Markit shareholder, click here to learn more about your rights and options.  


Sunesis Pharmaceuticals, Inc.
 (NASDAQ: SNSS) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Viracta Therapeutics, Inc. Under the terms of the merger agreement, Viracta stockholders will receive shares of newly issued Sunesis common stock. Sunesis stockholders are expected to own approximately 14% of the combined company on a fully diluted basis. If you are a Sunesis shareholder, click here to learn more about your rights and options.  


Front Yard Residential Corporation
 (NYSE: RESI) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a partnership led by Pretium and funds managed by Ares Management Corporation for $16.25 per share. If you are a Front Yard shareholder, click here to learn more about your rights and options.  


CIT Group Inc.
 (NYSE: CIT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to First Citizens BancShares, Inc. Under the terms of the merger agreement, CIT shareholders will receive 0.0620 shares of First Citizens class A common stock for each share of CIT common stock they own. If you are a CIT Group shareholder, click here to learn more about your rights and options.  

Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]  
https://www.halpersadeh.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-halper-sadeh-llp-reminds-shareholders-about-its-ongoing-merger-investigations-investors-are-encouraged-to-contact-the-firm–clct-info-snss-resi-cit-301182140.html

SOURCE Halper Sadeh LLP

Posted on

Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook

Ipsen Highlights New Strategic Priorities and Provides Mid-Term Financial Outlook

Focus on core therapeutic areas of Oncology, Rare Disease and Neuroscience

Commitment to invest in R&D supported by SG&A efficiencies

Priority on External Innovation strategy to build sustainable pipeline for future growth

PARIS–(BUSINESS WIRE)–
Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY), a specialty-care focused biopharmaceutical group, today will host a virtual Capital Markets Day to highlight the Group’s new strategic priorities with the aim of driving continued growth and bringing transformative medicines to patients.

David Loew, Chief Executive Officer of Ipsen stated: “Our new Group strategy positions Ipsen for long-term success by focusing together for patients and society. We will reinforce our commitment to Oncology, Rare Disease and Neuroscience by strengthening and accelerating our external innovation efforts and pipeline in clearly-defined segments. Through prioritization and collaboration, we will drive efficiencies to support investment in our pipeline. We are building on a strong foundation of engaged employees, agile development capabilities and global commercial footprint. I am energized to execute on our key strategic priorities to create long-term value for all stakeholders.”

Bring the full potential of innovative medicines to patients

Ipsen is focused on maximizing the value of its current Specialty Care product portfolio through commercial excellence and geographic expansion. The Group aims to maximize its core brands Somatuline® (lanreotide), Decapeptyl® (triptoreline) and Dysport® (botulinum toxin type A) and capture the full potential of its innovative oncology products Cabometyx® (cabozantinib) and Onivyde® (irinotecan liposome injection). If approved, the launch of palovarotene will be a key milestone to bring this medicine to patients with FOP and strengthen Ipsen’s presence in Rare Disease.

A strategic review of the Consumer Healthcare business is proceeding.

Build a high-value sustainable pipeline

Ipsen’s priority is to build a sustainable pipeline to drive long-term growth. Recent initiatives have prioritized the pipeline on the highest potential opportunities and progressed the transformation of the R&D organization. Ipsen is strengthening its external innovation efforts by targeting differentiated medicines in its three core therapeutics areas of Oncology, Rare Disease and Neuroscience, with a broader disease and modality scope than previously defined, and across all stages of clinical development.

Deliver efficiencies to enable targeted investment & growth

Ipsen is committed to generating efficiencies through a focused and agile operating model. Leveraging smart spending, streamlined operations, manufacturing efficiencies and optimizing digitalization, the Group will be able to reinvest in R&D and external innovation to fuel future growth.

Boost culture of collaboration & excellence

Patients and society are at the core of Ipsen’s mission, starting with fully engaged employees and a culture of accountability to perform and compete in the long-term. Ipsen is highly committed to its corporate social responsibility (CSR) initiatives which are centered around employees, community and the environment, as reflected throughout the organization and in the inclusion of responsibility metrics in management compensation.

Mid-term financial outlook and capital allocation strategy

Ipsen provides its financial outlook for the period 2020-20241:

  • Group Net Sales CAGR2 between +2% and +5%3, assuming potential additional indications
  • Commitment to invest in R&D supported by SG&A efficiencies
    • Lower SG&A as a percentage of net sales driven by further focus and optimization
    • Higher R&D as a percentage of net sales driven by external innovation strategy

External innovation is Ipsen’s number one priority for capital allocation. In support of its external innovation strategy, Ipsen expects to generate by 2024 a cumulative €3bn4 of firepower for pipeline expansion, excluding the sale of any assets.

Webcast

Ipsen will host a video webcast of the Capital Markets Day on Tuesday, 1 December 2020 from 2:00 p.m. to 5:00 p.m. CET (GMT+1) available at www.ipsen.com. Participants should log in to the webcast approximately 5 to 10 minutes prior to its start. No reservation is required to participate in the conference call.

Webcast link: https://ipsencapitalmarketsday2020.online-event.fr/

Please note this event will be streamed live. No dial-in number available.

A recording will be available for 14 days on Ipsen’s website.

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.fr

Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words “believes”, “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group is dependent on prices set for drugs, pricing and reimbursement reforms and is vulnerable to the potential withdrawal of certain drugs from the list of reimbursable products by governments, and the relevant regulatory authorities in its locations. In light of the economic crisis caused by the COVID-19 pandemic, there could be increased pressure on the pharmaceutical industry to lower drug prices. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2019 Universal Registration Document available on its website www.ipsen.com.

__________________________

1 Ipsen is on track to deliver its previous 2022 financial targets and is committed now to a new 2024 financial outlook

2 Compound Annual Growth Rate

3 At constant exchange rates and scope

4 Based on Net Debt remaining below 2.0x EBITDA

Financial Community

Eugenia Litz

Vice President, Investor Relations

+44 (0) 1753 627721

[email protected]

Media

Fanny Allaire

Director, Ipsen France Hub, Global Communications

+33 (0) 1 58 33 58 96

[email protected]

KEYWORDS: France Europe

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo
Posted on

WISeKey International Holding Ltd Announces Extraordinary General Meeting of Shareholders

WISeKey International Holding Ltd Announces Extraordinary General Meeting of Shareholders




Zug, Switzerland, December 1, 2020 – WISeKey International Holding Ltd (“WISeKey” or “Company”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity and IoT company, announced today that the Board of Directors has recommended certain proposals for shareholder approval at an Extraordinary General Meeting of Shareholders (“EGM“).

The EGM is expected to be held at 2pm CET on January 28, 2021. Due to the extraordinary situation in connection with the COVID-19 pandemic, WISeKey’s Board of Directors has decided to make use of the authority granted to it under the Swiss Federal Council Ordinance No. 3 on Measures to Combat the Coronavirus dated June 19, 2020 and require shareholders to exercise their voting rights at the EGM solely by giving electronic or written voting instructions to WISeKey’s independent voting rights representative, as further described in the invitation to the EGM, which will be published on or about December 11, 2020. It will not be possible for shareholders to attend the EGM in person.

The Board of Directors recommends shareholders to approve, among other things:

  • The creation of a special authorized share capital for the issuance of up to 12,327,506 new registered shares, par value CHF 0.05 each (“Class B Shares“), to arago GmbH’s (“arago“) sole shareholder apart from WISeKey, Mr. Hans-Christian Boos, or companies controlled by him, in exchange for all arago shares directly or indirectly held by Mr. Hans-Christian Boos.

As previously disclosed, WISeKey reached a binding agreement with arago for WISeKey to acquire through conversion of loan commitments and by guaranteeing arago’s existing indebtedness, a majority interest of 51% in arago. The acquisition of a controlling interest in arago is only the initial step in an overall transaction that would lead to a combination of the businesses of WISeKey and arago. If and when definitively agreed, the combination would be completed through the issuance by WISeKey of Class B Shares to arago’s remaining minority shareholder against contribution to WISeKey of all arago shares not yet held by WISeKey. The Board of Directors would only make use of its authority if binding agreements are executed and all conditions precedent to closing are satisfied.

  • The election of Mr. Hans-Christian  Boos, Managing Director and Founder of arago, as a new members of the Company’s Board of Directors, for a term extending until the next annual general meeting of shareholders. Mr. Boos studied computer science at ETH Zurich and the Technical University of Darmstadt. His ongoing research focuses on graph theory, machine reasoning and machine learning. Mr.  Boos is a member of the Digital Council advising the German Chancellor on digital policy and artificial intelligence.
  • An increase of the Board of Directors’ general authority to issue shares out of authorized share capital, corresponding to approximately 25.65% of the Company’s share capital (including the shares issued out of conditional share capital over 2020), in addition to the above-mentioned special authorized share capital for arago’s sole shareholder, for a further two-year period. The Board of Directors does not currently have specific plans to issue shares under the proposed general authorization. The Board of Directors believes, however, that providing the flexibility to issue shares quickly is a strategic benefit for the Company.
  • The creation of a conditional share capital on the basis of which the Company would have authority to issue registered shares, par value CHF 0.01, i.e. the Company’s shares not listed on the SIX Swiss Exchange (“Class A Shares“), to members of the Board of Directors and executive management. This proposed conditional share capital provides authority to issue Class A Shares representing approximately 4.75% of the Company’s share capital. The Board of Directors intends to implement a new “Class A Share WISeKey Stock Option Plan” pursuant to which members of the Board of Directors and the Company’s executive management could, subject to the plan being resolved upon and approved by the Board of Directors, receive options or other awards exercisable for Class A Shares. The Board of Directors believes that issuing Class A Shares, which are non-tradeable, will be beneficial to the Company, as it will require directors and executive management members to focus on the long-term strategy and development of the Company.
  • An increase of the Company’s conditional share capital whereby Class B Shares representing approximately 32.82% of the Company’s share capital (including the shares issued out of conditional share capital over 2020) will be reserved for Class B issuances in connection with convertible or similar financial instruments, and approximately 12.44% for Class B issuances under the WISeKey Stock Option Plan for the benefit of directors, executives, employees and consultants.

A short presentation of the agenda items by Carlos Moreira, CEO of WISeKey, and Peter Ward, CFO, will be available soon in the ‘Investors Relations’ section of the WISeKey website.

In addition, Dourgam Kummer has informed the Company that he will step down as a member of the Board of Directors with immediate effect. The Board thanks Mr. Kummer for his outstanding contribution to the Company.

About WISeKey

WISeKey (NASDAQ: WKEY; SIX Swiss Exchange: WIHN) is a leading global cybersecurity company currently deploying large scale digital identity ecosystems for people and objects using Blockchain, AI and IoT respecting the Human as the Fulcrum of the Internet. WISeKey microprocessors secure the pervasive computing shaping today’s Internet of Everything. WISeKey IoT has an install base of over 1.5 billion microchips in virtually all IoT sectors (connected cars, smart cities, drones, agricultural sensors, anti-counterfeiting, smart lighting, servers, computers, mobile phones, crypto tokens etc.).  WISeKey is uniquely positioned to be at the edge of IoT as our semiconductors produce a huge amount of Big Data that, when analyzed with Artificial Intelligence (AI), can help industrial applications to predict the failure of their equipment before it happens.

Our technology is Trusted by the OISTE/WISeKey’s Swiss based cryptographic Root of Trust (“RoT”) provides secure authentication and identification, in both physical and virtual environments, for the Internet of Things, Blockchain and Artificial Intelligence. The WISeKey RoT serves as a common trust anchor to ensure the integrity of online transactions among objects and between objects and people. For more information, visit www.wisekey.com.

Press and investor contacts:

WISeKey International Holding Ltd 

Company Contact:  Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
[email protected]		 WISeKey Investor Relations (US) 

Contact:  Lena Cati
The Equity Group Inc.
Tel: +1 212 836-9611
[email protected]

Disclaimer:

This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any shares or other securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FInSa’s predecessor legislation  or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.